An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is sponsoring charitable grants to expand community-focused patient navigator programs for individuals with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This initiative aims to eliminate care barriers, particularly in underserved populations. Grants of up to $50,000 will be awarded to U.S.-based organizations to enhance patient education and access to treatment. In its first year, Aurinia distributed $250,000 to five programs, showing significant improvements in patient care and adherence.
Positive
Aurinia pledged up to $50,000 in grants to support community programs addressing SLE and LN.
The previous year's program resulted in $250,000 funding for five patient navigation initiatives.
Negative
None.
– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions –
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for individuals living with SLE/LN. LN is a serious manifestation of SLE that can cause irreversible kidney damage and kidney failure and significantly affects more Black, Asian, and Hispanic individuals than non-Hispanic White individuals. Selected applicants may receive up to $50,000 over a one-year period.
The Request for Proposal (“RFP”) invites U.S. based charitable organizations to submit proposals that outline the development and execution of patient navigation programs that address barriers to screening, treatment, and supportive care for individuals living with SLE and LN. Grants will be awarded based on grantee ability to collaborate with local lupus centers (community or academic) and ability to deliver outcomes that:
Educate patients on the importance of routine screenings and medical appointments
Enhance patient/provider communication
Ensure patient’s basic needs are met (address social determinants of health)
Empower patients to make informed decisions about their health
Bridge access gaps
Connect patients with resources needed to receive ongoing treatment and medical care
Preference will be given to programs that support underserved communities, specifically, Blacks, Hispanics, and Asians.
In the first year of the grants program, Aurinia awarded $250,000 in Grants to support 5 patient navigation programs for a 12-month period (2021-2022). Throughout this time, grant recipients convened regularly to share lessons learned, best practices, as well as program metrics.
“The results from the first year of patient navigation grants illustrate the measurable impact these programs can have on improving diagnosis and disease management and supporting better adherence to medical appointments and treatments,” said Jessica Bateman, Advocacy Relations, Aurinia Pharmaceuticals. “We remain committed to this important program and to doing our part to mitigate the barriers to health equity and ultimately improve outcomes for those living with SLE and LN.”
Organizations are encouraged to submit applications by June 10, 2022. The full RFP can be found here.
About Lupus Nephritis
Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and approximately one out of three of these individuals develop LN. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals of Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
What is Aurinia Pharmaceuticals' program for SLE and LN?
Aurinia Pharmaceuticals is sponsoring grants to support community-focused patient navigator programs aimed at improving care for individuals with systemic lupus erythematosus (SLE) and lupus nephritis (LN).
How much funding is available for patient navigation programs by Aurinia?
Organizations can receive up to $50,000 in funding for patient navigation programs focused on SLE and LN.
What was the outcome of the first year of Aurinia's grant program?
In the first year, Aurinia awarded $250,000 in grants to support five patient navigation programs, which showed significant improvements in patient care.
What is the deadline for the grant applications from Aurinia?
The deadline for grant applications is June 10, 2022.
Why does Aurinia prioritize underserved communities in its grant program?
Aurinia prioritizes underserved communities like Blacks, Hispanics, and Asians to address health equity and improve outcomes for those disproportionately affected by SLE and LN.
